Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
MINNEAPOLIS—Kim Kelderman, the Chief Executive Officer of Bio-Techne Corp (NASDAQ:TECH), recently executed a series of stock transactions involving the company’s common stock. On January 27, Kelderman sold a total of 13,392 shares, generating proceeds of approximately $1.04 million. The shares were sold at prices ranging from $77.19 to $77.95 per share. The transaction occurred as Bio-Techne, currently valued at $11.4 billion, trades at a P/E ratio of 74.7, indicating a premium valuation according to InvestingPro analysis.
In addition to the sales, Kelderman also exercised stock options to acquire 13,392 shares of Bio-Techne common stock at an exercise price of $37.70 per share. Following these transactions, Kelderman holds 39,004 shares directly.
These transactions were reported in a Form 4 filing with the Securities and Exchange Commission, reflecting changes in Kelderman’s beneficial ownership of Bio-Techne securities.
In other recent news, Bio-Techne Corporation has scored a legal victory against Miltenyi Biotec, with the court ruling in favor of Bio-Techne in a patent dispute. The ruling entitles Bio-Techne to monetary damages and reimbursement for costs incurred in proving the infringement. In recent developments, Bio-Techne reported a 4% year-over-year organic revenue growth in its first quarter for Fiscal Year 2025, with revenues reaching $289.5 million. The company’s adjusted earnings per share saw a slight increase to $0.42 from the previous year’s $0.41.
Bio-Techne has also been forging strategic alliances, partnering with Waters Corporation (NYSE:WAT) and Leader Life Sciences. The partnership with Waters Corporation aims to enhance biotherapeutic development processes, while the alliance with Leader Life Sciences expands Bio-Techne’s reach in the Gulf Cooperation Council countries. Baird, a financial services firm, increased its price target for Bio-Techne from $82 to $84, maintaining an Outperform rating, following the company’s strong quarterly results.
In executive moves, Bio-Techne has granted its Executive Vice President and Chief Financial Officer, James Hippel, a one-time award of 34,634 restricted stock units as a retention incentive. These recent developments underscore Bio-Techne’s strategic growth initiatives and its effective navigation through market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.